Ascent Group’s GSK GSK Stock Holding History

Ascent Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,700	Closed	-$204K	–	820
2026 Q1	$204K	Buy	+3,700	New	+$201K	0.01%	727

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ascent Group's GSK Position: Q2 2026 in Review

Ascent Group sold out of GSK (GSK) in Q2 2026, closing a stake of 3,700 shares — an estimated $204K sold.

Ascent Group first reported a position in GSK in Q1 2026 and held it in 1 quarter. The position peaked at $204K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Ascent Group reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Ascent Group sold 3,700 GSK shares in Q2 2026, an estimated $204K.
Ascent Group first reported a position in GSK in Q1 2026 and held it in 1 quarter.
Ascent Group's GSK position peaked at $204K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.